LBRX — LB Pharmaceuticals Inc Common Stock stock price, charts and financials

Latest market price

45.00

+2.16+5.04%

Overview Short InterestFilings

LBRXQT86LB Pharmaceuticals Inc Common Stock·NASDAQ

Overview Short InterestFilings

45.00+5.04%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 STOK+7.14%$31.67 TSHA+7.27%$6.20 AUPH+2.47%$14.93 MESO+2.28%$14.80 URGN+3.45%$39.92 TYRA+1.53%$32.53 IOVA+0.93%$4.36

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	28.68M	Perf Week	23.17%

Market Cap	1.23B	Forward P/E	-	EPS next Y	-4.25	Insider Trans	-	Shs Float	20.76M	Perf Month	28.15%

Enterprise Value	866.51M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	20.52%	Perf Quarter	36.30%

Income	-25.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	16.85	Perf Half Y	99.72%

Sales	0.00	P/B	3.24	EPS next Y	-23.55%	ROA	-9.95%	Short Interest	4.26M	Perf YTD	92.45%

Book/sh	13.22	P/C	3.36	EPS next 5Y	-	ROE	-17.68%	52W High	46.56 -3.36%	Perf Year	-

Cash/sh	12.76	P/FCF	-	EPS past 3/5Y	-	ROIC	-12.23%	52W Low	14.03 220.66%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	10.48% 7.45%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	2.69	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	35.68	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	76.64	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	35.68	EPS Q/Q	26.23%	SMA20	23.32%	Beta	0.55	Target Price	46.71

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	35.49%	Rel Volume	3.13	Prev Close	42.84

Employees	27	LT Debt/Eq	0.01	Earnings	Jun 25	SMA200	71.89%	Avg Volume	278.65K	Price	45.00

IPO Date	Sep 11, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.56% -	Net Debt/EBITDA	8.12	Volume	872,089	Change	5.04%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-03-26	Reiterated	Piper Sandler		$78
Jul-20-26	Initiated	BMO Capital	Outperform	$46
Jul-07-26	Initiated	Wolfe Research	Outperform	$45
May-17-26	Reiterated	Roth Capital		$31 → $37
Apr-27-26	Initiated	H.C	Buy	$45
Apr-10-26	Initiated	Craig-Hallum		$36
Mar-27-26	Reiterated	Stifel Nicolaus		$35 → $40
Jan-09-26	Initiated	Roth Capital	Buy	$31
Dec-11-25	Reiterated	Stifel Nicolaus		$27 → $35
Oct-06-25	Initiated	Leerink	Outperform	$34

Latest News

Jul-29-26

Jul-29-2608:02AM

LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded WarrantsBenzinga

08:00AM

LB Pharmaceuticals Announces $150 Million Private Placementglobenewswire.com

Jul-22-26

Jul-22-2608:00AM

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophreniaglobenewswire.com

Jul-21-26

Jul-21-2605:34AM

BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46Benzinga

Jul-10-26

Jul-10-2604:38PM

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-07-26

Jul-07-2606:40AM

Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45Benzinga

Jun-30-26

Jun-30-2608:00AM

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operationsglobenewswire.com

Company

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0
Gross Profit	0	0	0	0
Selling, General and Administrative Excl. Other	14	14	4	1
Research and Development	17	51	8	1
Other Operating Expense	-1	0	-1	1
Operating Income	-30	-65	-11	-3
Interest Expense	0	0	5	2
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	5	2	10	-9
Net Income Before Taxes	-25	-63	-6	-14
Income Taxes	0	0	0	0
Consolidated Net Income	-25	-63	-6	-14
Net Income From Continuing Operations	-25	-63	-6	-14
Net Income	-25	-63	-6	-14
EPS (Recurring)	-1.00	-17.83	-1.77	-4.05
EPS (Basic, Before Extraordinaries)	-1.00	-17.83	-1.77	-4.05
EPS (Diluted)	-1.00	-17.83	-1.77	-4.05
EBITDA	-25	-63	-1	-12
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	—	—	—	—
Gross Margin	—	—	—	—
Operating Margin	—	—	—	—
Net Margin	—	—	—	—
Shares Outstanding	25	4	4	4
Market Capitalization	557	—	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.